Published in Am J Respir Cell Mol Biol on January 22, 2010
Novel expression of a functional glycine receptor chloride channel that attenuates contraction in airway smooth muscle. FASEB J (2011) 1.04
tPA-S481A prevents neurotoxicity of endogenous tPA in traumatic brain injury. J Neurotrauma (2012) 0.87
tPA regulates pulmonary vascular activity through NMDA receptors. Am J Physiol Lung Cell Mol Physiol (2011) 0.84
Fibulin-5 binds urokinase-type plasminogen activator and mediates urokinase-stimulated β1-integrin-dependent cell migration. Biochem J (2012) 0.82
Urokinase plasminogen activator regulates pulmonary arterial contractility and vascular permeability in mice. Am J Respir Cell Mol Biol (2011) 0.81
tPA-S(481)A prevents impairment of cerebrovascular autoregulation by endogenous tPA after traumatic brain injury by upregulating p38 MAPK and inhibiting ET-1. J Neurotrauma (2013) 0.78
The asthma epidemic. N Engl J Med (2006) 8.60
The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med (2001) 5.28
Remodeling in asthma and chronic obstructive lung disease. Am J Respir Crit Care Med (2001) 3.59
Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest (1996) 2.97
The biology of nitrogen oxides in the airways. Am J Respir Crit Care Med (1994) 2.90
Constitutive and inducible nitric oxide synthase gene expression, regulation, and activity in human lung epithelial cells. Proc Natl Acad Sci U S A (1994) 2.41
Airway smooth muscle dynamics: a common pathway of airway obstruction in asthma. Eur Respir J (2007) 2.16
The role of nitric oxide in cardiovascular diseases. Mol Aspects Med (2005) 1.86
Extravascular fibrin, plasminogen activator, plasminogen activator inhibitors, and airway hyperresponsiveness. J Clin Invest (2004) 1.70
Serpin-resistant mutants of human tissue-type plasminogen activator. Nature (1989) 1.61
In vitro and in vivo effects of tPA and PAI-1 on blood vessel tone. Blood (2003) 1.53
Urokinase is required for the pulmonary inflammatory response to Cryptococcus neoformans. A murine transgenic model. J Clin Invest (1996) 1.45
Urokinase receptor-deficient mice have impaired neutrophil recruitment in response to pulmonary Pseudomonas aeruginosa infection. J Immunol (2000) 1.43
Neutralizing the neurotoxic effects of exogenous and endogenous tPA. Nat Neurosci (2006) 1.38
LRP and alphavbeta3 mediate tPA activation of smooth muscle cells. Am J Physiol Heart Circ Physiol (2006) 1.26
Binding of urokinase to low density lipoprotein-related receptor (LRP) regulates vascular smooth muscle cell contraction. J Biol Chem (2002) 1.26
Plasminogen activators contribute to age-dependent impairment of NMDA cerebrovasodilation after brain injury. Brain Res Dev Brain Res (2005) 1.23
Human mast cell tryptase activates single-chain urinary-type plasminogen activator (pro-urokinase). J Biol Chem (1994) 1.19
Amino acid residues that affect interaction of tissue-type plasminogen activator with plasminogen activator inhibitor 1. Proc Natl Acad Sci U S A (1990) 1.13
Excitotoxicity in the lung: N-methyl-D-aspartate-induced, nitric oxide-dependent, pulmonary edema is attenuated by vasoactive intestinal peptide and by inhibitors of poly(ADP-ribose) polymerase. Proc Natl Acad Sci U S A (1996) 1.12
Plasminogen activators contribute to impairment of hypercapnic and hypotensive cerebrovasodilation after cerebral hypoxia/ischemia in the newborn pig. Stroke (2005) 1.11
Serine protease inhibitors: novel therapeutic targets for stroke? J Cereb Blood Flow Metab (2000) 1.05
Urokinase-derived peptides regulate vascular smooth muscle contraction in vitro and in vivo. FASEB J (2000) 1.04
Induction of the plasminogen activator system by mechanical stimulation of human bronchial epithelial cells. Am J Respir Cell Mol Biol (2006) 1.04
Glutamate receptors and asthmatic airway disease. Trends Pharmacol Sci (1999) 1.04
Inhalation of urokinase-type plasminogen activator reduces airway remodeling in a murine asthma model. Am J Physiol Lung Cell Mol Physiol (2008) 0.99
Airway smooth muscle as a target of asthma therapy: history and new directions. Respir Res (2006) 0.96
Identification of an inhibitor of tissue-type plasminogen activator-mediated fibrinolysis in human neutrophils. A role for defensin. J Biol Chem (1995) 0.95
Toward safer thrombolytic agents in stroke: molecular requirements for NMDA receptor-mediated neurotoxicity. J Cereb Blood Flow Metab (2008) 0.94
Mechanisms altering airway smooth muscle cell Ca+ homeostasis in two asthma models. Respiration (2008) 0.93
Association of urokinase-type plasminogen activator with asthma and atopy. Am J Respir Crit Care Med (2007) 0.92
Tissue plasminogen activator modulates the cellular and behavioral response to cocaine. Proc Natl Acad Sci U S A (2009) 0.92
Urokinase-type plasminogen activator modulates airway eosinophil adhesion in asthma. Am J Respir Cell Mol Biol (2006) 0.91
Urokinase potentiates PDGF-induced chemotaxis of human airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol (2003) 0.91
Regulation of single chain urokinase binding, internalization, and degradation by a plasminogen activator inhibitor 1-derived peptide. J Biol Chem (1997) 0.90
Potential target sites in peripheral tissues for excitatory neurotransmission and excitotoxicity. Toxicol Pathol (2000) 0.89
Restoration of serine protease-inhibitor interaction by protein engineering. J Biol Chem (1990) 0.88
Ionotropic glutamate receptors in lungs and airways: molecular basis for glutamate toxicity. Am J Respir Cell Mol Biol (2003) 0.87
Plasminogen activator inhibitor-1 plasma concentration in allergic asthma patients during allergen challenge. Int Arch Allergy Immunol (2007) 0.85
Plasminogen activator inhibitor-1 in the pathogenesis of asthma. Exp Biol Med (Maywood) (2004) 0.85
Regulation of the single-chain urokinase-urokinase receptor complex activity by plasminogen and fibrin: novel mechanism of fibrin specificity. Blood (2004) 0.80
Plasminogen activator inhibitor-1 (PAI-1) and urokinase plasminogen activator (uPA) in sputum of allergic asthma patients. Folia Histochem Cytobiol (2008) 0.79
Effect of exogenous glutamate and N-Methyl-D-aspartic acid on spontaneous activity of isolated human ureter. Int J Urol (2007) 0.77
Selegiline, an MAO-B inhibitor, attenuates airway smooth muscle contraction in the rat trachea. J Pharm Pharmacol (2004) 0.77
International consensus report on the investigation and management of primary immune thrombocytopenia. Blood (2009) 7.72
Counterpoint: should fibrinolytics be routinely administered intrapleurally for management of a complicated parapneumonic effusion? No. Chest (2014) 2.37
Prophylactic fibrinolysis through selective dissolution of nascent clots by tPA-carrying erythrocytes. Nat Biotechnol (2003) 2.03
Graduated responsibility for pathology residents: no time for half measures. Arch Pathol Lab Med (2013) 1.97
Platelet factor 4 localization in carotid atherosclerotic plaques: correlation with clinical parameters. Thromb Haemost (2003) 1.91
How I treat heparin-induced thrombocytopenia. Blood (2012) 1.85
Structure of human urokinase plasminogen activator in complex with its receptor. Science (2006) 1.84
Cerebrovascular thromboprophylaxis in mice by erythrocyte-coupled tissue-type plasminogen activator. Circulation (2008) 1.84
GM-CSF in the lung protects against lethal influenza infection. Am J Respir Crit Care Med (2011) 1.83
Nuclear translocation of urokinase-type plasminogen activator. Blood (2008) 1.66
Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. Blood (2004) 1.63
Post-transcriptional regulation of urokinase-type plasminogen activator receptor expression in lipopolysaccharide-induced acute lung injury. Am J Respir Crit Care Med (2008) 1.62
Dynamic antibody-binding properties in the pathogenesis of HIT. Blood (2012) 1.59
Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications. Blood (2005) 1.59
In vitro and in vivo effects of tPA and PAI-1 on blood vessel tone. Blood (2003) 1.53
Rational design and characterization of platelet factor 4 antagonists for the study of heparin-induced thrombocytopenia. Blood (2012) 1.50
Transgenic mice studies demonstrate a role for platelet factor 4 in thrombosis: dissociation between anticoagulant and antithrombotic effect of heparin. Blood (2004) 1.50
How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment. Blood (2012) 1.40
Neutralizing the neurotoxic effects of exogenous and endogenous tPA. Nat Neurosci (2006) 1.38
Congenital and acquired thrombocytopenia. Hematology Am Soc Hematol Educ Program (2004) 1.38
Blockade of tissue factor: treatment for organ injury in established sepsis. Am J Respir Crit Care Med (2003) 1.38
Blockade of tissue factor-factor X binding attenuates sepsis-induced respiratory and renal failure. Am J Physiol Lung Cell Mol Physiol (2005) 1.31
ICAM-directed vascular immunotargeting of antithrombotic agents to the endothelial luminal surface. Blood (2003) 1.28
LRP and alphavbeta3 mediate tPA activation of smooth muscle cells. Am J Physiol Heart Circ Physiol (2006) 1.26
Binding of urokinase to low density lipoprotein-related receptor (LRP) regulates vascular smooth muscle cell contraction. J Biol Chem (2002) 1.26
Structural basis of interaction between urokinase-type plasminogen activator and its receptor. J Mol Biol (2006) 1.25
Determinants of PF4/heparin immunogenicity. Blood (2007) 1.25
Plasminogen activators contribute to age-dependent impairment of NMDA cerebrovasodilation after brain injury. Brain Res Dev Brain Res (2005) 1.23
Genetic analysis of autoantibodies in idiopathic thrombocytopenic purpura reveals evidence of clonal expansion and somatic mutation. Blood (2002) 1.21
Frozen section of lung specimens. Arch Pathol Lab Med (2005) 1.21
uPA modulates the age-dependent effect of brain injury on cerebral hemodynamics through LRP and ERK MAPK. J Cereb Blood Flow Metab (2008) 1.18
Antithrombotic thrombocytes: ectopic expression of urokinase-type plasminogen activator in platelets. Blood (2003) 1.18
Regulation of neovascularization by human neutrophil peptides (alpha-defensins): a link between inflammation and angiogenesis. FASEB J (2004) 1.17
Human alpha-defensin regulates smooth muscle cell contraction: a role for low-density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor. Blood (2002) 1.16
Blood clearance and activity of erythrocyte-coupled fibrinolytics. J Pharmacol Exp Ther (2004) 1.16
Rebuttal from Drs Colice and Idell. Chest (2014) 1.16
Pathogenesis of pleural fibrosis. Respirology (2004) 1.16
Sustained thromboprophylaxis mediated by an RBC-targeted pro-urokinase zymogen activated at the site of clot formation. Blood (2010) 1.14
Prophylactic thrombolysis by thrombin-activated latent prourokinase targeted to PECAM-1 in the pulmonary vasculature. Blood (2007) 1.14
Inhibition of pathologic retinal neovascularization by alpha-defensins. Blood (2005) 1.13
Direct interaction of the kringle domain of urokinase-type plasminogen activator (uPA) and integrin alpha v beta 3 induces signal transduction and enhances plasminogen activation. Thromb Haemost (2006) 1.12
Integrin alphaMbeta2 orchestrates and accelerates plasminogen activation and fibrinolysis by neutrophils. J Biol Chem (2004) 1.12
The matrix unloaded: aerosolized heparin or urokinase for pulmonary fibrosis. Am J Respir Crit Care Med (2003) 1.12
Human complement receptor type 1-directed loading of tissue plasminogen activator on circulating erythrocytes for prophylactic fibrinolysis. Blood (2006) 1.11
Plasminogen activators contribute to impairment of hypercapnic and hypotensive cerebrovasodilation after cerebral hypoxia/ischemia in the newborn pig. Stroke (2005) 1.11
The fibrinolytic system and the regulation of lung epithelial cell proteolysis, signaling, and cellular viability. Am J Physiol Lung Cell Mol Physiol (2008) 1.11
Neutrophil alpha-defensins cause lung injury by disrupting the capillary-epithelial barrier. Am J Respir Crit Care Med (2010) 1.10
uPA impairs cerebrovasodilation after hypoxia/ischemia through LRP and ERK MAPK. Brain Res (2008) 1.09
Liquid Biopsy in Lung Cancer: A Perspective From Members of the Pulmonary Pathology Society. Arch Pathol Lab Med (2016) 1.08
Pseudomonas aeruginosa outer membrane protein F is an adhesin in bacterial binding to lung epithelial cells in culture. Microb Pathog (2002) 1.08
Thank you, no. Arch Pathol Lab Med (2010) 1.07
"No pay, no play": game over. Arch Pathol Lab Med (2012) 1.07
Targeting of a mutant plasminogen activator to circulating red blood cells for prophylactic fibrinolysis. J Pharmacol Exp Ther (2009) 1.05
Urokinase-type plasminogen activator potentiates lipopolysaccharide-induced neutrophil activation. J Immunol (2003) 1.05
Monocyte-bound PF4 in the pathogenesis of heparin-induced thrombocytopenia. Blood (2010) 1.04
Critical role of integrin alpha 5 beta 1 in urokinase (uPA)/urokinase receptor (uPAR, CD87) signaling. J Biol Chem (2003) 1.03
Regulation of plasminogen activator inhibitor-1 expression by tumor suppressor protein p53. J Biol Chem (2008) 1.03
Anchoring fusion thrombomodulin to the endothelial lumen protects against injury-induced lung thrombosis and inflammation. Am J Respir Crit Care Med (2009) 1.03
Platelet factor 4 enhances the binding of oxidized low-density lipoprotein to vascular wall cells. J Biol Chem (2002) 1.02
Red blood cells-coupled tPA prevents impairment of cerebral vasodilatory responses and tissue injury in pediatric cerebral hypoxia/ischemia through inhibition of ERK MAPK activation. J Cereb Blood Flow Metab (2009) 1.02
Induction of plasminogen activator inhibitor-1 by urokinase in lung epithelial cells. J Biol Chem (2003) 1.02
Validation of interobserver agreement in lung cancer assessment: hematoxylin-eosin diagnostic reproducibility for non-small cell lung cancer: the 2004 World Health Organization classification and therapeutically relevant subsets. Arch Pathol Lab Med (2012) 1.02
tPA contributes to impaired NMDA cerebrovasodilation after traumatic brain injury through activation of JNK MAPK. Neurol Res (2011) 1.01
Defining a second epitope for heparin-induced thrombocytopenia/thrombosis antibodies using KKO, a murine HIT-like monoclonal antibody. Blood (2002) 1.01
The kringle stabilizes urokinase binding to the urokinase receptor. Blood (2003) 1.00
The glycocalyx protects erythrocyte-bound tissue-type plasminogen activator from enzymatic inhibition. J Pharmacol Exp Ther (2007) 1.00
Immune thrombocytopenia. Hematology Am Soc Hematol Educ Program (2010) 1.00
Blood-brain barrier permeability and tPA-mediated neurotoxicity. Neuropharmacology (2010) 1.00
Signaling, delivery and age as emerging issues in the benefit/risk ratio outcome of tPA For treatment of CNS ischemic disorders. J Neurochem (2010) 0.98
δ ENaC: a novel divergent amiloride-inhibitable sodium channel. Am J Physiol Lung Cell Mol Physiol (2012) 0.98
The kringle domain of urokinase-type plasminogen activator potentiates LPS-induced neutrophil activation through interaction with {alpha}V{beta}3 integrins. J Leukoc Biol (2005) 0.97
Regulation of urokinase receptor expression by p53: novel role in stabilization of uPAR mRNA. Mol Cell Biol (2007) 0.97
Interactions of platelet factor 4 with the vessel wall. Semin Thromb Hemost (2004) 0.94
Regulation of urokinase receptor expression by phosphoglycerate kinase. Am J Respir Cell Mol Biol (2004) 0.94